Showing 1 - 10 of 33
Persistent link: https://www.econbiz.de/10001860156
Persistent link: https://www.econbiz.de/10003387041
Persistent link: https://www.econbiz.de/10009620010
Persistent link: https://www.econbiz.de/10009620445
Persistent link: https://www.econbiz.de/10011553243
Persistent link: https://www.econbiz.de/10008936343
Persistent link: https://www.econbiz.de/10011405921
Persistent link: https://www.econbiz.de/10002886886
Settlements of drug patent disputes that involve a potential payment from the brand to the generic signal a possible collusive profit split with a threat to competition, and have undergone intensive scrutiny in the literature on law and economics. A common feature of these brand-generic...
Persistent link: https://www.econbiz.de/10012938770
After receiving FDA approval, a generic drug manufacturer can launch "at risk" before conclusion of any patent infringement litigation, but it risks paying damages if it loses. The generic can eliminate the risk by waiting to launch until the appeals process is complete but waiting has downsides...
Persistent link: https://www.econbiz.de/10012616579